お知らせ • Mar 28
Charming Medical Limited Announces Resignation of Independent Director Josephine Yan Yeung, Effective March 27, 2026 Charming Medical Limited announced that on March 27, 2026, Ms. Josephine Yan Yeung notified the Company of her resignation as an independent director, effective March 27, 2026, in order to pursue other business commitments. On March 27, 2026, the Board of Directors of the Company accepted and approved Ms. Yeung's resignation. The Company is in the process of identifying a suitable replacement and expects to fill the vacancy by April 2, 2026. お知らせ • Jan 08
Charming Medical Limited Announces Board Changes Charming Medical Limited on December 23, 2025, Mr. Leut Ming Gung notified the Company of his resignation as an independent director, effective December 31, 2025, in order to pursue other business commitments. Mr. Gung’s resignation was not a result of any disagreement with the Company’s operations, policies, or procedures. On January 5, 2026, the Board of Directors of the Company accepted and approved Mr. Gung’s resignation. On January 5, 2026, the Board of Directors, Nominating Committee, and the Compensation Committee approved by resolutions and confirmed the appointment of Mr. Yin Jiang as a director of the Company, with an annual compensation of HKD 240,000, effective upon approval of the resolutions, until his successor is duly elected and qualified, or until his earlier death, resignation or removal. The Board has determined Mr. Jiang is an “independent” director under applicable U.S. Securities and Exchange Commission and Nasdaq Marketplace Rules. Mr. Jiang will be serving on the Board of Directors as a non-employee, independent director. Mr. Jiang has also been named as the chairman of the Compensation Committee and a member of the Audit Committee and Nominating Committee of the Company. Mr. Jiang has been involved in fund management activities since 2016. In 2017, he founded Panshi Capital, a private equity fund, which was acquired in 2019 by a multi-billion RMB institution in China. He also has experience in artificial intelligence and blockchain technologies and holds multiple invention patents and software copyrights in these fields. In 2013, Mr. Jiang founded Panzhong Technology Co. Ltd., a technology company focused on fiber-optic communication and high-performance computing applications. From 2004 to 2013, he served as a software test engineer at Cisco WebEx. Mr. Jiang received a Bachelor of Science degree in Applied Physics from the University of Science and Technology of China in 2004 and holds a securities investment fund qualification certificate issued by the Asset Management Association of China. お知らせ • Dec 20
Robbins LLP Informs Investors of the Charming Medical, Limited Securities Class Action Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Charming Medical, Limited securities between October 10, 2025 and November 12, 2025. The Company claims to "enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology." The Allegations: Robbins LLP is Investigating Allegations that Charming Medical, Limited (MCTA) Engaged in a Fraudulent Stock Promotion Scheme. According to the complaint, defendants failed to disclose that: (1) Charming was the subject of a fraudulent stock promotion scheme involving social media based misinformation and impersonated financial professionals; (2) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) Charming's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price. Plaintiff alleges that in the weeks leading up to November 12, 2025, Charming's share price surged from the initial public offering price of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming's stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors. On November 12, 2025, the SEC halted trading of Charming's stock. The stock remains halted because the Company has not provided the information regulators required to lift the suspension. Board Change • Oct 22
High number of new directors Independent Director Josephine Yeung was the last director to join the board, commencing their role in 2025. お知らせ • Oct 21
Charming Medical Limited has completed an IPO in the amount of $6.4 million. Charming Medical Limited has completed an IPO in the amount of $6.4 million.
Security Name: Class A Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,600,000
Price\Range: $4
Discount Per Security: $0.28